

## ASSESSING IF BUPRENORPHINE TREATMENT IS BEST REFERENCES

1. Richert Torkel, Johnson Björn. Long-term self-treatment with methadone or buprenorphine as a response to barriers to opioid substitution treatment: the case of Sweden. *Harm Reduct J*. 2015;12. doi:10.1186/s12954-015-0037-2.
2. Lemon SC, Friedmann PD, Stein MD. The impact of smoking cessation on drug abuse treatment outcome. *Addict Behav*. 2003;28(7):1323-1331.
3. Farmer CM, Lindsay D, Williams J, et al. Practice Guidelines for Buprenorphine for the Treatment of Opioid Use Disorders: Results of an Expert Panel Process. 2015;36(2).
4. FDA. CLIA - Clinical laboratory improvement amendments - currently waived analytes. 2016.
5. Kraus ML, Alford DP, Kotz MM, et al. Statement of the American Society of Addiction Medicine Consensus Panel on the Use of Buprenorphine in Office-Based Treatment of Opioid Addiction. *J Addict Med*. 2011;5(4):254-263.
6. Klimas Jan, Field Catherine-Anne, Cullen Walter, et al. Psychosocial interventions to reduce alcohol consumption in concurrent problem alcohol and illicit drug users: Cochrane Review. *Syst Rev*. 2013;2.
7. Gudín JA, Mogali S, Jones JD. Risks, management, and monitoring of combination opioid, benzodiazepines, and/or alcohol use. *Postgrad Med*. 2013;125(4):115-130.
8. FDA. Medication Guide: Zubsolv Sublingual Tablet (CIII). July 2013.
9. Sterling S, Chi F, Hinman A. Integrating Care for People With Co-Occurring Alcohol and Other Drug, Medical, and Mental Health Conditions. *Alcohol Res Health*. 2011;33(4):338-349.
10. Sees KL, Clark HW. When to begin smoking cessation in substance abusers. *J Subst Abuse Treat*. 1993;10(2):189-195.
11. Reid MS, Mickalian JD, Delucchi KL, et al. An acute dose of nicotine enhances cue-induced cocaine craving. *Drug Alcohol Depend*. 1998;49(2):95-104.
12. Baca CT, Yahne CE. Smoking cessation during substance abuse treatment: what you need to know. *J Subst Abuse Treat*. 2009;36(2):205-219.
13. Reid MS, Selzer J, Rotrosen J. Smoking Cessation treatment at Substance Abuse Rehabilitation Programs. *Northeast ATTC Newsl*. 2006;5(2):2-5.
14. Prochaska JJ, Delucchi K, Hall SM. A meta-analysis of smoking cessation interventions with individuals in substance abuse treatment or recovery. *J Consult Clin Psychol*. 2004;76(6):1144-1156.
15. Fiore MC, Jaén CR, Baker TB, et al. *Treating Tobacco Use and Dependence: 2008 Update*. Rockville, MD: U.S. Department of Health and Human Services. Public Health Service; 2008.
16. Potter JS, Marino EN, Hillhouse MP. Buprenorphine/naloxone and methadone maintenance treatment outcomes for opioid analgesic, heroin, and combined users:

- findings from starting treatment with agonist replacement therapies (START). *J Stud Alcohol Drugs*. 2013;74(4):605-613.
17. Kleber H, Weiss R, Anton R, et al. [Practice guideline for the treatment of patients with substance use disorders](#). Vol 3rd edition. American Psychiatric Association; 2010.
  18. FSMB. [Model Policy on DATA 2000 and Treatment of Opioid Addiction in the Medical Office](#). *FSMB Website*. 2013.
  19. Renner J, Saxon A, Levounis P. [Buprenorphine Update and Evolving Standards of Care](#). IPS: The Mental Health Services Conference. October 2015. New York City.
  20. Fishbain DA, Cole B, Lewis J, et al. [What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/or aberrant drug-related behaviors? A structured evidence-based review](#). *Pain Med*. 2008;9(4):444-459.
  21. Wu LT, Woody GE, Yang C, et al. [Subtypes of nonmedical opioid users: results from the National Epidemiologic Survey on Alcohol and Related Conditions](#). *Drug Alcohol Depend*. 2010;112:69-80.
  22. USDHHS. [Medication Assisted Treatment for Opioid Use Disorders Reporting Requirements](#). 2016.
  23. USPSTF. [Draft Update Summary: Unhealthy Alcohol Use in Adolescents and Adults, Including Pregnant Women: Screening and Behavioral Counseling Interventions - US Preventive Services Task Force](#). August 2016.
  24. FDA. [Drug Safety Podcasts - FDA Drug Safety Podcast: FDA urges caution about withholding opioid addiction medications from patients taking benzodiazepines or CNS depressants: careful medication management can reduce risks](#). 2017.
  25. Farmer Carrie M, Lindsay Dawn, Williams Jessica, et al. [Practice Guidance for Buprenorphine for the Treatment of Opioid Use Disorders: Results of an Expert Panel Process](#). *Subst Abuse*. 2015;36(2):209-216. doi:10.1080/08897077.2015.1012613.
  26. Fiellin DA, Rosenheck RA, Kosten TR. [Office-based treatment for opioid dependence: reaching new patient populations](#). *Am J Psychiatry*. 2001;158(8):1200-1204.
  27. Mee-Lee D. [The ASAM Criteria](#). Vol 3rd edition. ASAM; 2013.
  28. McClellan AT, McKay JR. [Components of successful addiction treatment](#). In: *N: Graham AW, Schultz TK, Mayo-Smith MF, Ries RK, Wilford BB, Eds. Principles of Addiction Medicine*. Vol Third Edition. Chevy Chase, Md: American Society of Addiction Medicine; 2003:3.
  29. Stine SM, Greenwald MK, Kosten TR. [Pharmacologic interventions for opioid addiction](#). In: *In: Graham AW, Schultz TK, Mayo-Smith MF, Ries RK, Wilford BB, Eds. Principles of Addiction Medicine*. Vol Third Edition. Chevy Chase, Md; 2003.
  30. Fishman MJ, Mee-Lee D, Schulman GD, et al. [Supplement to the ASAM Patient Placement Criteria on the Management of Alcohol Use Disorders](#). Baltimore, MD: Lippincott, Williams & Wilkins, Inc; 2010.
  31. VA/DoD. [VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders](#). *VA/DoD*. 2015.
  32. Hopfer CJ, Khuri E, Crowley TJ, et al. [Adolescent heroin use: a review of the descriptive and treatment literature](#). *J Subst Abuse Treat*. 2002;23(3):231-237.
  33. SAMHSA. [Treatment of Adolescents With Substance Use Disorders. Treatment Improvement Protocol Series, No. 32](#). Rockville, Md: Center For Substance Abuse Treatment; 1999.

34. Subramaniam G, Levy S. [PCSS-MAT Guidance: Treatment of opioid dependent adolescents and young adults using sublingual buprenorphine](#). 2010.
35. ASAM. [The ASAM National Practice Guideline For the Use of Medications in the Treatment of Addiction Involving Opioid Use](#). June 2015.
36. Dowell D, Haegerich TM, Chou R. [CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016](#). *MMWR Recomm Rep*. 2016;65(1):1-49. doi:10.15585/mmwr.rr6501e1er.
37. Conigliaro J, Reyes CD, Parran TV, et al. [Principles of screening and early intervention](#). In: *In: Graham AW, Schultz TK, Mayo-Smith MF, Ries RK, Wilford BB, Eds. Principles of Addiction Medicine*. Vol Third Edition. Chevy Chase, Md: American Society of Addiction Medicine; 2003.
38. CADCA. [Comprehensive Addiction and Recovery Act \(CARA\)](#). *CADCA.org*. 2016.